96 BIOTECHNOLOGY
after launch. Tis gives users the assurance they need that their initial extractable and leachable qualification work and data remain valid every time they operate a single-use Flexsafe bioprocess.
Sartorius has also moved to tackle another issue raised by single-use solutions; security of supply. Te company says that this is guaranteed as a result of its long- term contracts with suppliers and its business continuity plans with defined safety stocks and global manufacturing capabilities – including resin manufacturing.
To begin with the company is launching a 1-200 litre range of the new bags for validation purposes. Bags for single- use reactors and additional applications such as storage, mixing, shipping freeze and thaw will be rolled on a step-by-step basis.
Off-the-shelf production plant Worldwide demand for monoclonal antibodies for the treatment of cancer and rheumatoid arthritis – as well as for a new generation of vaccines – is increasing, driven by the global ageing population, and the global effort to reduce the incidence of vaccine-preventable diseases.
Although increasing in popularity, monoclonal antibodies are among the world’s most expensive categories of drugs. Te reason for this is that to retrieve the antibodies, the manufacturers must go through a long process of harvesting cell cultures and then purifying the antibodies. Once this process is completed, the drug-makers have removed proteins and other cell debris present in the cell culture, leaving only the desired antibodies. Te production facilities needed to do this are an added cost.
An off-the-shelf solution from GE Healthcare known as KUBio can help meet the manufacturing needs of cancer- fighting monoclonal antibodies. Effectively a set of preassembled units, a cGMP-compliant KUBio facility capable of manufacturing over 100 kg/ year of monoclonal antibodies can be up and running in 14-18 months. However, the concept would not be a success without the high-performance, single-use technology at its heart (Fig. 2). Tis includes GE Healthcare’s WAVE bioreactor, part of the company’s ReadyToProcess platform – which in turn is part of its ecomagination portfolio. Ecomagination is an initiative which helps GE’s customers to improve their bottom line and reduce environmental impact.
“KUBio represents the first manufacturing activity in- country-for-country in the growing economies, supporting the sustainable supply of biologic drugs, reducing import costs and increasing accessibility and affordability to local populations. We are very proud of this product and it could make a real difference to emerging economies,” said GE Life Sciences enterprise solution leader, Olivier Loeillot.
Fig. 2. The KUBio concept has single- use technology at its heart.
Single-use addresses specialised needs D
uring scale-up of cell culture in the manufacturing of biotherapeutics, specialised approaches are used to address the novel
characteristics of these bioproduction processes. Cell culture conditions and consistent growth are critical to the biochemistry of the active components during expression, recovery, and purification. According to Life Technologies, single-use
technologies address these specialised needs. Single-use products have revolutionised the field of biomanufacturing: “With single-use technologies, it’s now possible to make small amounts of drug product that might be suitable for preclinical and clinical testing.
www.scientistlive.com
Prior to the availability of these single-use systems, this would have required substantial facilities to produce the material needed,” says the company. Today single-use technologies are used throughout
the workflow of bioproduction, from buffer and media preparation to bioreactor cultures for vaccines to the storage and shipping of intermediates and bulk biologics. To this end the company now offers a
comprehensive suite of single-use technology products to support all bioproduction needs, including bioprocess containers and bags, manifold assemblies, outer support containers, single-use fermenters,
single-use bioreactors, and single-use mixers. Life’s single-use technologies are also designed to integrate perfectly with its portfolio of cell culture serum, media, supplements, buffers, and other process liquids. For example, the stirred-tank reactor is one of the
most commonly utilised reactor types in biotechnology. Life’s single-use bioreactors (SUB) are designed as stirred-tank reactors for animal cell culture, using traditional stainless steel bioreactor principles for optimal cell culture performance - with the novel advantage of utilising completely single-use product contact surfaces to help reduce contamination and minimise clean-up.
Meanwhile, Applikon Biotechnology is focused on pre- sterilised and pre-qualified single- use modules, citing as benefits faster facility set-up, reduction in down time, simplified validation and more efficient use of plant floor space.
Te company offers a selection of single-use bioreactors in three basic formats: flexible bag bioreactors; rigid stirred tank bioreactors; and flexible stirred tank bioreactors. All bioreactor designs offer measurement and control of important process parameters.
Te Appliflex flexible bag systems support both classical electrochemical sensor technology and optical sensors for pH and dissolved oxygen. Appliflex bioreactors are supplied in 10 litre, 20 litre and 50 litre total volumes.
For its part the CellReady bioreactor is a disposable version of the Applikon three-litre glass autoclavable bioreactor and can be used as a direct replacement of these systems.
Te HyClone SUB (single use bioreactor) is available in volumes ranging from 50-2000 litres. Te system can be equipped with classic sensors or with PreSens fluorophor sensor technology for pH and dissolved oxygen.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120